# A Vaccine Trial Called ‘Unethical’ and a ‘Unique’ Opportunity: Is It On or Off?
The fate of a controversial U.S.-funded hepatitis B vaccine trial in Guinea-Bissau remains uncertain as of this week, caught between competing claims from American health officials and African regulators grappling with serious ethical concerns.
## The Study at the Center of the Controversy
The **Centers for Disease Control and Prevention awarded a $1.6 million grant** to researchers at the University of Southern Denmark to conduct a trial examining different timing strategies for hepatitis B vaccination in newborns[1]. The proposed study would compare two groups: some newborns in Guinea-Bissau would receive the hepatitis B vaccine at birth, while others would follow the country’s standard practice of receiving it at 6 weeks old. Researchers aimed to measure differences in “overall health outcomes” between the two cohorts[1].
On the surface, this might seem like a straightforward comparative study. But experts have raised significant objections that transformed what appeared to be routine research into an international controversy.
## Why Experts Call It Unethical
The ethical concerns are multifaceted and substantial. First, many experts questioned whether the trial would even produce useful results for U.S. policy, particularly given recent developments. The Trump administration recently overturned a long-standing recommendation that all babies in the United States receive the hepatitis B vaccine at birth—making it unclear how findings from Guinea-Bissau would inform American vaccination policy[1].
More troubling is the context within Guinea-Bissau itself. The country had been planning to launch a **universal birth dose policy**, which aligns with World Health Organization recommendations[1]. By conducting a trial that withholds the birth dose from some newborns, researchers would essentially be preventing some infants from accessing what Guinea-Bissau had determined to be the optimal vaccination schedule. Though Guinea-Bissau experienced a coup in November 2025 and has since delayed its universal birth dose policy until 2028, the fundamental ethical tension remains: why would researchers test whether a delayed approach is acceptable when global health authorities recommend immediate protection[1]?
The study design itself drew criticism. Measuring broad “overall health outcomes” rather than specific vaccine efficacy raises questions about whether the trial is appropriately designed to answer meaningful scientific questions[1].
## The Confusion Over Status: On or Off?
The trial’s status has become remarkably murky. Last week, The Guardian reported that the trial had been canceled, citing an Africa CDC briefing[1]. However, U.S. health officials immediately contradicted this, stating the trial was moving forward as planned[1].
This week brought further clarification—though not resolution. Guinea-Bissau’s public health minister, Quinhin Nantote, announced that plans for the study have been **paused pending further review** from national authorities[1]. “There has been no sufficient coordination in order to make a final decision regarding that study,” Nantote told reporters during a press briefing held by the Africa Centres for Disease Control and Prevention[1].
Crucially, however, Nantote did not declare the trial definitively canceled. The briefing indicated that “the trial could still move forward,” suggesting the pause is temporary pending regulatory and ethical review[1]. The Africa CDC announced it would send officials to Guinea-Bissau to provide technical support for this review process[1].
## Who Gets to Decide?
A significant tension underlies this controversy: **national sovereignty versus international research agendas**. During Thursday’s briefing, Jean Kaseya, the Africa CDC’s director general, repeatedly emphasized that any authorization for clinical studies must be granted by the countries hosting them[1].
“It’s not Africa CDC that will say, this clinical trial will take place or not. It’s not any other international body that will come to say, this clinical trial will take place or not. It’s not a foreign country that will come and say, this one will take place. It’s the sovereignty of the country,” Kaseya stated[1].
This assertion of African agency came amid broader tensions. Futurism reported that an unnamed U.S. health official had described the Africa CDC as “a powerless, fake organization attempting to manufacture credibility by repeating its claims publicly”[1]. The Africa CDC leadership used Thursday’s briefing partly to defend its work and legitimacy across the continent[1].
## The Current Moment
As of Thursday, January 22, 2026, the trial remains in limbo. U.S. health officials maintain that from their perspective, the study is moving forward as planned, though they have not publicly responded to recent developments[1]. Guinea-Bissau has paused the process pending further review. The Africa CDC is providing technical support but has made clear the final decision rests with Guinea-Bissau’s national authorities[1].
## What This Reveals
This situation illustrates fundamental tensions in global vaccine research: the balance between scientific opportunity and ethical obligations, the importance of informed national decision-making, and the challenge of conducting research in developing countries while respecting both scientific rigor and human dignity. Whether the trial ultimately proceeds will depend on Guinea-Bissau’s regulatory and ethical review process—a process that should not be rushed, given the stakes involved.
Original source: NPR News – A vaccine trial is called ‘unethical’ and a ‘unique’ opportunity. Is it on or off?
Leave a Reply